Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | HPGDS | O60760 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110022 | 0.88 | ALDH1A1 (0.60) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL2783103 | 0.87 | MEN1 (0.83) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL2783104 | 0.87 | MEN1 (0.83) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL10750868 | 0.87 | ALDH1A1 (0.78) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL10750872 | 0.87 | ALDH1A1 (0.78) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL13320683 | 0.87 | KDM4E (0.82) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL14801969 | 0.87 | KDM4E (0.82) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL111201 | 0.87 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| Tranilast SCHEMBL10978582 | 0.85 | MEN1 (1.00) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| Tranilast SCHEMBL29875 | 0.85 | MEN1 (1.00) | ALDH1A1HPGDKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-9839640-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2017-12-12 | — | — | US | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-12-04 | — | — | US | disclosed |
| US-8624056-B2 | Halogenated analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2014-01-07 | — | — | US | disclosed |
| US-20130310386-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2013-11-21 | — | — | US | disclosed |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | THE UNIVERSITY OF MELBOURNE (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885KDM4E 1194/4885 |
| US-20130310386-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885KDM4E 1194/4885 |
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | NFATC1, AADAC, NAT1 | ALDH1A1 201/4885HPGD 630/4885KDM4E 1605/4885 |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | ALDH1A1 242/4885HPGD 1175/4885KDM4E 1397/4885 |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885KDM4E 1194/4885 |
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885KDM4E 1194/4885 |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | ALDH1A1 242/4885HPGD 1175/4885KDM4E 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.